The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil by Isidori, Am et al.
Clinical Study
The SIAMS-ED Trial: A National, Independent, Multicentre
Study on Cardiometabolic and Hormonal Impairment of Men
with Erectile Dysfunction Treated with Vardenafil
Andrea M. Isidori,1 Giovanni Corona,2 Antonio Aversa,1
Daniele Gianfrilli,1 Emmanuele A. Jannini,3 Carlo Foresta,4 Mario Maggi,5
Andrea Lenzi,1 and SIAMS-ED Study Group6
1 Department Experimental Medicine, Sapienza University, 00161 Rome, Italy
2 Endocrinology Unit, Maggiore-Bellaria Hospital, 40133 Bologna, Italy
3 University of Tor Vergata, Department of System Medicine, 00133 Rome, Italy
4Centre Cryopreservation of Male Gamete, University of Padova, 35122 Padua, Italy
5 Biomedicine, University of Florence, 50121 Florence, Italy
6 SIAMS, Italian Society of Andrology and Sexual Medicine, Italy
Correspondence should be addressed to Andrea Lenzi; andrea.lenzi@uniroma1.it
Received 15 September 2013; Revised 8 December 2013; Accepted 28 December 2013; Published 15 May 2014
Academic Editor: Janaka Karalliedde
Copyright © 2014 Andrea M. Isidori et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Increased cardiovascular risk has been associated with reduced response to proerectile drugs.The Italian Society of Andrology and
Sexual Medicine (SIAMS) promoted an independent, multicenter study performed in 604 men (55 ± 12 yrs) suffering from erectile
dysfunction (ED) to assess multiple health outcomes and response to 6-month vardenafil challenge in a real-life setting. Overall,
30.8% men had metabolic syndrome. Cardiovascular risk stratification revealed a greater number of ED subjects with moderate
risk of a major adverse cardiovascular event than the general population (𝑃 < 0.01). Age-adjusted pulse pressure was positively
correlated with ED severity and negatively with androgens and waist circumference (𝑃 < 0.01). A decline in total testosterone was
observed with increasing arterial pulse pressure (𝑃 < 0.05), which was not accompanied by compensatory LH rise. Follow-up on
185 men treated with vardenafil in an nonrandomized, open, single-arm trial documented a significant rise in IIEF-5 (delta = 6.1 ±
4.8) that was maintained in men with high cardiovascular risk. Mild adverse events occurred in <5%, with no differences between
cardiovascular risk classes. In summary, ED is a frequent symptom in patients with an elevated, but often unknown, risk of future
cardiovascular events. Androgens predict vascular resistance in ED patients. Vardenafil’s response and safety profile were preserved
in subjects with higher cardiovascular risk.
1. Introduction
Large discrepancies have been reported for the prevalence of
ED in the general population, and CV risk accounts for a
significant part of this variability. Over the age of 40 years,
moderate to severe ED is reported in about 30 to 35% of
men [1]. However in men with hypertension the prevalence
ranges from 26% to 68% and in thosematching the diagnostic
criteria for metabolic syndrome (MS) it ranges from 34% to
90% [2–4], with a progressive impairment of erectile function
(EF) in parallel with the number of metabolic syndrome
criteria met [5]. Since scientific societies revisited the diag-
nostic criteria for metabolic syndrome, there have been a
number of studies describing its association with ED. Despite
a clear pathophysiological link, it is still under debate whether
the diagnosis of metabolic syndrome offers any diagnostic
advantage, to the validated CV risk charts, for management
of ED in real-life settings [6–8].
There is an unmet need of good CV risk biomarkers for
ED subjects [9]. Recent epidemiological studies showed that
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reduced testosterone (TT) levels in men are associated with
high blood pressure (BP), left ventricularmass, and increased
cardiovascular mortality [10]. This may be due to the stiff-
ening of large arteries, as observed in men under androgen
ablation therapy for prostate cancer [11]. Pulse pressure (PP),
the arithmetic difference between systolic (SBP) and diastolic
blood pressure (DBP) [12, 13], has been considered to reflect
arterial stiffness, an independent CV risk factor for elderly
and diabetic patients [14–17].We have previously reported an
association between PP and arteriogenic ED [18], suggesting
a negative association between penile blood flow and PP even
after adjustment for mean BP and other confounders such as
metabolic syndrome. Nevertheless, despite encouraging pre-
liminary data, the relationship between testosterone levels,
hypertension, and ED is far from being clarified [19, 20].
In Europe, systematic coronary risk evaluation (SCORE)
charts have been validated for CVR. However, charts not
developed in the country of application can lead to inad-
equate risk stratification [21]. The Italian Progetto Cuore
(Heart Project) has been extensively tested and shows an
excellent overlapwith theMediterranean populations derived
from the European SCORE [22]. The performance of such
defined CV risk classes in predicting the severity of ED has
yet to be documented.
Finally, men with several CVRFs are also less likely to
benefit from standard ED treatments [23, 24]. Sponsored
clinical trials for drug registration purposes are often biased
by the tendency to recruit populations with lower CVRs than
seen in end users in a real-life setting [25]. Therefore, the
safety and efficacy of PDE5i in high CV risk populations
require further investigation.
For all these reasons the Italian Society of Andrology
and Sexual Medicine promoted a nationwide, independent,
multicentre, two-phase study, consisting in a large cross-
sectional analysis followed by an interventional, nonrandom-
ized, open-label, single-arm trial carried out in the real-life
settings. Its aim was to address all the following clinical
questions. (1) What is the prevalence of cardiovascular
and metabolic risk factors in unselected men attending an
outpatient clinic for ED? (2) Does the diagnostic criteria of
metabolic syndrome add any significant contribution to the
CV risk chart for ED stratification? (3) What are the best
determinants of the severity of ED in real-life settings? (4) Is
PP an independent contributor to ED? (5)Does PPdependon
androgen levels? (6) Is vardenafil’s response and safety pre-
served in subjects with higher CV risk?
2. Methods
2.1. Study Protocol. In this independent, multicentre, open-
label, prospective, noncomparative, interventional study, 604
consecutive men with ED (>6-month duration), as assessed
by the international index of erectile function-5 (IIEF-5) [26],
were recruited (Figure 1). The study was conducted from
2009 to 2011 at 18 public andrology and sexual medicine
centres in Italy (see contributors). The protocol consisted of
screening visit (V1), a 4-week washout period from any ED
treatment (V2) and a 5/6-month treatment with vardenafil
(any dose), prescribed at the investigator’s discretion, and
final response evaluation visit (V3). The interventional study
was non-randomized and single blind. Subjects taking steroid
hormones and other drugs known to affect directly testos-
terone levels were excluded from the study (Figure 1).
The entire study, from recruitment of centres to comple-
tion of the patient case report form (CRF), was carried out
using web-based applications. The trial was registered on the
Italian Society of Andrology and Sexual Medicine website
(http://www.siams.info/) in 2008. Participation was open
to any Italian NHS andrology outpatient clinic with proven
experience in conducting ED trials. Interested sites could
apply online, and eligible sites received the protocol kit by e-
mail. In two start-up meetings, a training session was orga-
nized to guarantee uniformity in ultrasound techniques and
diagnostic criteria. Monitoring of CRF completion, statistical
analysis, and quality control was centralized at the Depart-
ment of Experimental Medicine, Sapienza University of
Rome.The protocol was approved by the PoliclinicoUmberto
I Ethics Committee (Authorization 304/09) and by each
local participating centre. All patients were asked to sign an
informed consent form.
General details, medical and surgical history, concomi-
tant medication history, and CV risk score—evaluated
using the PC based risk engine derived from the Progetto
Cuore study—were recorded at V1 [27]. The Progetto Cuore,
launched in the late 1990s by the Italian Ministry of Health
and based on the European systematic coronary risk eval-
uation (SCORE) risk charts, uses a computerized engine to
record and follow up cardiovascular mortality and morbidity
in the adult Italian population [21]. It allows us to collect
data from Italian GPs that have downloaded the software for
the stratification of CVR. The algorithm is used by a large
number of GPs that are entering, remotely, the risk factors
of their patients to provide an updated national estimate
of the CV risk in the general Italian population. Epidemi-
ological data on CV risk of the population are periodically
released, enabling comparison of subgroups of interest (the
latest release can be found at http://www.cuore.iss.it/). The
database can be queried to generate the reference dataset of
subgroup of interest; for the present study we used estimates
from all males who were entered in the engine and matched
for age, in the same time frame, with no other restriction
criteria.
The following data were collected at baseline and after 6
months: general physical examination, weight, height, body
mass index (BMI), waist circumference (WC), systolic blood
pressure and DBP, PP calculated as the difference between
systolic blood pressure and DBP, heart rate (HR), and the
IIEF-5 questionnaires.
An IIEF-5 score of 21 or less confirmed ED, whose
severity was classified into 4 categories: mild [17–21], mild
to moderate [12–16], moderate [8–11], and severe [<8].
These categories were also merged to enable comparison of
the first three (mild to moderate) against the last (severe). A
clinical score based on a physician-guided interview was also
analysed, as previously described [28]. Metabolic syndrome
was defined according to the National Cholesterol Education
Program’s Adult Treatment Panel III (NCEP-ATP-III) [29].
Hormonal assessment included TT, luteinizing hormone
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Figure 1: Study design (STARD plot).
(LH), and follicle stimulating hormone (FSH) [30]. Testos-
terone wasmeasured by electrochemiluminescence (method:
Immulite 2000 Siemens, Milan, Italy; within and between-
assay coefficients of variation were 5.1% and 7.2%), while
FSH and LHwere measured using direct chemiluminescence
(ADVIA Centaur, Bayer Co, Germany). A penile colour
doppler ultrasound (PDCU) was also evaluated for all treated
patients after a challenge with vasoactive agents according to
previously published procedures [31]. Efficacy of vardenafil
treatment was evaluated as variation from baseline in IIEF-5
scores (Δ-IIEF-5).
2.2. Response to Treatment in High CV Risk Subjects.
Recruited subjects were stratified according to CV risk class
as high (≥III, i.e., ≥10% risk of major cardiovascular event,
[MACE]) versus low risk (<III, i.e., <10%). The primary effi-
cacy variable was the variation in the IIEF-5 score at week 22–
26 or last observation carried forward (LOCF) compared to
baseline (Δ-IIEF-5). Secondary efficacy variables included the
percentage of subjects achieving a “return-to-normal” erec-
tile function (IIEF-5 > 22) and change in ED severity class.
Safety variables included adverse events (AEs) recorded at all
visits after visit 2 and vital signs, supine, and standing heart
rate and BP.
Efficacy was analysed in both the intent-to-treat (ITT)
population (patients who had taken at least one dose of
study medication and had a LOCF) and the per-protocol
(PP) population (patients who satisfied the ITT and had
completed the 22 weeks of treatment). The safety population
included all subjects taking at least one dose of vardenafil and
having at least one reported postbaseline measurement. The
incidence of treatment-emergent adverse events was analysed
and reported to the central EC.
2.3. Statistical Analysis. The analyses were performed by ITT
and PP set strategies, using SPSS 19.0 (SPSS Inc., Chicago, IL,
USA). An alpha value threshold of 0.05 was used.The sample
size was estimated to achieve a >80% power for rejection
of the null hypothesis that a greater than 20% difference in
the baseline-to-endpoint improvement in erectile function
measured by IIEF-5 (Δ-IIEF-5) would occur between low and
high CV risk classes. The expected ratio of low versus high
CVR classes was estimated on the basis of the distribution
in the general population (3 : 1). Sample size was therefore
defined on the basis of the smaller group (high risk). Signifi-
cance at the 0.05 level was required to reject the null hypoth-
esis. All statistical tests were two tailed. Continuous variables
were tested for normality (Shapiro-Wilk test); normal data
were presented as mean ± SD, or as median with 25th–75th
percentiles, if not otherwise specified. Comparisonswere per-
formed, according to their distribution, using Student’s 𝑡-test
for paired and unpaired data or Pearson’s 𝜒2 test and Mann-
Whitney Wilcoxon’s signed-rank test. Associations among
variables were tested with Spearman’s correlation analysis.
Linear regression analysis was used to explore determinants
of total IIEF-5 score including, in a stepwise approach,
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all variables with a significant univariate association with
measures of EF. Logistic regression analysis was used to
identify predictors of severe ED. All analyses were performed
adjusting for the effect of centre (18 recruiting sites). Changes
in IIEF-5 score before and after treatment were analysed with
a repeated measures analysis of variance model adjusted for
confounding factors (ANCOVA). The same model was used
to test whether response to treatment differed among groups
with different CV risks.
3. Results
3.1. Characteristics of the Study Population. Six hundred and
four men (median age of 55 years) with ED were assessed
for eligibility, and 539 (89.2%) were enrolled in and com-
pleted the observational study. After completion, 253 spon-
taneously continued into the interventional study and were
prescribed vardenafil on demand (10/20mg, recommended
twice weekly) for 5 consecutive months; 183 (73%) completed
the interventional trial (Figure 1). The study population was
representative of a real-life outpatient’s clinic (Table 1): 17.8%
had severe ED, 21.5% had moderate, 37.7% had mild-to-
moderate, and 22.9% had mild ED. A large number of them
were receiving treatments for underlying conditions: 253
(42%) ofmenwere under treatment for hypertension, 56 (9%)
were under treatment for dyslipidaemia, and 87 (14%) were
under treatment for diabetes. However, a significant propor-
tion (24%) of them, despite abnormal metabolic, hormonal,
or pressure values, were not taking any treatment. Subjects
taking steroid hormones and other drugs known to affect
directly testosterone levels were not included in the study
(Figure 1).
3.2. What Is the Prevalence of Cardiovascular and Metabolic
Risk Factors in Unselected Men with ED? One-third of
patients (30.8%) met the diagnosis of metabolic syn-
drome (according to ATPIII criteria). Specifically, 33.2% had
reduced HDL cholesterol, 23.6% had increased waist circum-
ference, 67% had high blood pressure (of which 49.9% had
systolic, and diastolic had systolic and diastolic hypertension,
42% had isolated systolic and 8.1% had isolated diastolic
hypertension), 37.5% had hypertriglyceridaemia, and 31.7%,
had high blood glucose.
Stratification of CV risk (according to the Progetto Cuore
risk chart) categorised 28.6% and 30.2% of subjects as classes
I and II (10-year risk of incipient MACE <10%), 21.5% as
class III (10–15%), 12.3% as class IV (15–20%), and 5.4% and
1.9% as classes V and VI (>20% risk). A comparison of the
prevalence of metabolic syndrome components in the CV
risk stratification is shown in Figure 2. This analysis shows
that while the distributions of metabolic syndrome criteria
and CV risk scores were similar in low and high risk classes
(I-II or V-VI), for the intermediate classes, they were clearly
divergent. A comparison of the CV risk of the ED population
compared to the age-matched general population (𝑛 = 68890,
mean age 54.9) is shown in Figure 3. The comparison was
possible since the CV risk was assessed using the com-
puterized engine (Progetto Cuore) distributed by the NIH;
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Figure 2: Prevalence of CV risk (CVR) classes and number of
metabolic syndrome (MS) criteria in the study population.
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Figure 3: Distribution of CV risk in the general population and in
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the same algorithm is used for periodical remote monitoring
of CV risk by GPs. The 68890 men used in the comparison
were age-matched men who were entered in the system
during the same time frame of our study. It can be seen
that the ED population had a significantly higher prevalence
of moderate CV risk (classes III and IV: 18% versus 33.8%
𝑃 < 0.001), an essentially similar prevalence of high CV risk
(classes V and VI: 7.9 versus 7.4%) and a lower prevalence of
low CVR.
3.3. Does the Diagnostic Criteria of Metabolic Syndrome
Add Any Significant Contribution to the CV Risk Chart for
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Table 1: Baseline parameters (604 recruited patients). Data are presented as mean ± standard deviation when normally distributed, median
[25th–75th percentiles] when skewed, and as percentages when categorical.
Parameter
Age Years 55.3 ± 12.08
Anthropometrics
Weight (kg) 82.9 ± 13.46
BMI (kg/m2) 27.4 ± 4.15
Waist circumference (cm) 99.1 ± 11.84
Metabolism
Glycaemia (mg/dL) 102 [94–114]
HDL cholesterol (mg/dL) 45.9 ± 11.03
Triglycerides (mg/dL) 139 ± [100–175]
Cardiovascular
Systolic BP (mmHg) 131.41 ± 10.48
Diastolic BP (mmHg) 82.17 ± 6.96
Pulse pressure 49.25 ± 10.4
Heart rate 75.88 ± 8.17
Hormonal
FSH (IU/mL) 6.4 ± 10.3
LH (IU/mL) 4.86 ± 5.43
Total testosterone (ng/dL) 4.04 ± 1.7
Penile CDU Peak systolic velocity (cm/s
2) 40.4 ± 13.1
Penile resistive index 0.83 ± 0.27
Prevalence of diagnostic criteria (%)
CV risk class
I (MACE risk < 5%) 28.6
II (MACE risk 5–10%) 30.2
III (MACE risk 10–15%) 21.5
IV (MACE risk 15–20%) 12.3
V (MACE risk 20–30%) 5.4
VI (MACE risk > 30%) 1.9
Metabolic syndrome (yes) ≥3 criteria 30.8
Blood pressure ≥130/85 or treatment 67.0
Triglycerides ≥150mg/dL (≥1.7mmol/L) 37.5
HDL cholesterol ≤40mg/dL (≤1.03mmol/L) 33.2
Fasting glucose ≥110mg/dL (≥6.1mmol/L) 31.7
Waist ≥102 cm 23.6
ED severity (IIEF-5 class)
Mild (17–21) 22.9
Mild to moderate (12–16) 37.7
Moderate (8–11) 21.5
Severe (<8) 17.8
Prediction of ED? The age-adjusted association between the
investigated variables, CV risk and ED severity is reported
in Table 2. The CV risk, stratification risk was strongly asso-
ciated with impaired EF, even when controlled for age and
smoking. Similarly, PP was associated either with increasing
CV risk or with declining IIEF-5 score. Interestingly, the
number of metabolic syndrome criteria was not correlated
with ED severity as measured by IIEF-5. Although there was
a correlation between MS criteria and CV risk class, possibly
because the latter includes diabetes, no correlation was found
between metabolic syndrome and PP. Total testosterone was
inversely correlated with age, CVR, PP, and waist circum-
ference, but not with MS. In contrast, waist circumference
was directly correlated with CVR, PP, metabolic syndrome,
and TT, but not with IIEF-5 score. All correlations remained
significant when the analyses were performed on subjects
not on antihypertensive medications. After adjustment for
confounding factors (age, smoking, and center), no signifi-
cant correlation was found between metabolic syndrome and
other investigated variables.
3.4. What Are the Best Determinants of the Severity of ED
in Real-Life Settings for Routine Use in Clinical Practice?
Regression analysis was performed to investigate the best
determinants of erectile function measured as total IIEF-5
score. Table 3 reports the odds ratio for severe ED when the
single components of the cardiometabolic risk and hormonal
variables were individually tested in a model adjusted for
age and centre. In a stepwise model, entering all variables
significantly correlated with IIEF-5 score, while CV risk
class (as number) was found to be the best independent
determinant of IIEF-5 total score (std 𝛽 = −0.279, 𝑃 < 0.001,
and Adj 𝑅2 = 7.4%). When cumulative variables, CV risk
class, or number of metabolic syndrome criteria were
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Table 2: Partial correlations adjusted for age and smoking.
Variable IIEF5 score IIEF54 categories
IIEF5
2 categories
CV risk
categories
Pulse
pressure
MS yes versus
no
MS number
of criteria Testosterone
IIEF-5 4 categories −0.949
∗
𝑃 = 0.000
IIEF-5 2 categories −0.815
∗
𝑃 = 0.000
0.874∗
𝑃 = 0.000
CVR categories −0.113
§
𝑃 = 0.045
0.156
‡
𝑃 = 0.005
0.142
§
𝑃 = 0.043
Pulse pressure −0.124
§
𝑃 = 0.013
0.112
§
𝑃 = 0.017
0.111
§
𝑃 = 0.018
0.148
‡
𝑃 = 0.006
MS yes versus no 0.093
𝑃 = 0.305
−0.052
𝑃 = 0.535
−0.056
𝑃 = 0.504
0.006
𝑃 = 0.952
0.081
𝑃 = 0.315
MS number of
criteria
0.039
𝑃 = 0.624
−0.026
𝑃 = 0.726
−0.05
𝑃 = 0.497
0.093
𝑃 = 0.267
0.052
𝑃 = 0.463
0.844∗
𝑃 = 0.000
Testosterone −0.031
𝑃 = 0.726
−0.078
𝑃 = 0.274
−0.017
𝑃 = 0.811
−0.149
§
𝑃 = 0.046
−0.057
𝑃 = 0.453
−0.072
𝑃 = 0.566
−0.123
𝑃 = 0.253
Waist
circumference
−0.003
𝑃 = 0.962
0.021
𝑃 = 0.743
−0.048
𝑃 = 0.453
0.175
§
𝑃 = 0.012
0.146
§
𝑃 = 0.018
0.302
‡
𝑃 = 0.003
0.245
‡
𝑃 = 0.008
−0.197
§
𝑃 = 0.035
IIEF-5 categories: mild ED versus mild to moderate ED versus moderate ED versus severe ED.
IIEF-5 2 categories: mild and mild to moderate ED versus moderate and severe ED.
∗
𝑃 < 0.0001, †𝑃 < 0.001, ‡𝑃 < 0.01, and §𝑃 < 0.05.
Table 3: Odds ratio for severe ED. Variables are individually tested
in a model adjusted for age, smoking, and centre. Significant ORs
are highlighted in bold.
Odds ratio CI 𝑃 value
BMI 1.037 .980–1.098 .202
Waist (cm) 1.005 .982–1.028 .665
Diastolic BP (mmHg) .980 .948–1.012 .216
Diastolic hypertension
(categorical) 1.192 .727–1.955 .487
Systolic BP (mmHg) 1.000 .982–1.018 .995
Systolic BP (categorical) 1.132 .681–1.883 .633
Pulse pressure (PP) 1.012 .988–1.037 .334
PP normalized for DBP 5.128 1.087–24.545 .040
Total cholesterol .993 .985–1.000 .051
HDL cholesterol .994 .968–1.021 .677
Triglycerides 1.000 .997–1.003 .951
Fasting glycemia 1.004 .997–1.011 .237
Hb1Ac 1.296 1.027–1.634 .029
Diabetes (categorical) 2.072 1.172–3.666 .012
Testosterone .786 .625–.988 .039
CV risk class 1.437 1.105–1.868 .007
excluded from the model, the following variables were found
to be significant independent contributors to IIEF-5: age (std
𝛽 = −0.199, 𝑃 = 0.001, and Adj 𝑅2 = 3.6%), PP (std 𝛽 =
−0.144, 𝑃 = 0.0, and ΔAdj 𝑅2 = +2.0%), and testosterone
(std 𝛽 = 0.213, 𝑃 = 0.040, and ΔAdj 𝑅2 = +1.2%). The role
of CVR, age, testosterone, and PP was confirmed when IIEF-
5 categories or clinical severity of ED classes were used (data
not shown). Among the five components of the metabolic
syndrome, only glycaemia was a significant determinant of
IIEF-5 score (std 𝛽 = −0.147, 𝑃 = 0.016, and Adj 𝑅2 =
1.8%). Finally, a comprehensive model of logistic regression
analysis for the identification of subjects with severe ED,
including global scores (CVR class and MetS diagnosis), was
tested. This confirmed that CV risk class was the single best
significant contributor to the model, with 88% of affected
subjects correctly predicted (OR = 1.57 CI: 1.29–1.83).
3.5. Does PP Depend on Androgen Levels? The distribution
of PP and testosterone values according to CV risk class
is reported in Figure 4. Significantly higher PP values were
found in classes above CVR-III (class I versus IV, 𝑃 < 0.001, I
versus V, 𝑃 = 0.010, II versus VI, 𝑃 < 0.001, and III versus IV,
𝑃 < 0.001). Testosterone was also stratified for CVR, showing
an inverse trend, with higher CV risk associated with lower
testosterone levels (class I versus IV, 𝑃 = 0.031, I versus V,
𝑃 = 0.022, and II versus IV, 𝑃 = 0.011). The distribution of
testosterone and LH according to PP is reported in Figure 5.
Interestingly, the progressive decline in testosterone was
not accompanied by a compensatory rise in LH indicat-
ing that high CV risk is associated with secondary, rather
than primary, hypogonadism. The novelty of this finding
is the progressive impairment to the hypothalamo-pituitary-
testicular axis with increasing CV risk and PP (Figure 5).The
determinants of PP are analysed in Table 4. Age, waist cir-
cumference, and testosterone were found to be determinants
for PP, explaining up to 12% of variability. BMI, glycaemia,
HDL, and triglycerides did not contribute to the model.
3.6. Is Response to Vardenafil Maintained in High CV Risk
Subjects? Treatment with vardenafil determined a significant
increase in IIEF-5 scores from baseline (12.45 ± 4.96 ver-
sus 18.40 ± 5.09, 𝑃 < 0.001; see Figure 6). At baseline,
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Table 4: Linear regression analysis for the determinants of pulse
pressure in the study population.
𝐵-coefficient SE of 𝐵 𝑃 value
Variable entered in the model
(constant) 21.350 12.742 0.098
Age 0.192 0.097 0.041
Total testosterone −1.231 0.616 0.040
Waist circumference 0.306 0.156 0.044
Excluded variables
HDL cholesterol 0.199 0.142 0.166
Triglycerides 0.004 0.011 0.709
Glycaemia −0.015 0.029 0.613
BMI −0.622 0.394 0.119
Adj 𝑅2 = 0.124.
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Figure 6: Response to vardenafil measured by the international
index of erectile function (IIEF-5).
the IIEF-5 score was <21 for the entire study population,
while after treatment it had normalized in 32%of the subjects,
with 62% achieving an improvement ≥5 points and 81%
showing an improvement variation in the ED severity class
(severe, moderate-to-severe, mild-to-moderate, and mild).
Consistent results were obtained even in men with moderate
and severe ED (40.6%, with IIEF-5 score <12 at baseline). In
these men, there was a mean increase in IIEF-5 score of 112%
(from 7.58±2.95 to 16.06±5.61, 𝑃 < 0.001). In the remaining
patients (59.4%) with IIEF-5 score>12, themean increase was
27% (from 15.78±2.85 to 20.00±4.00, 𝑃 < 0.001).The global
net increase was 48%.
When stratified for PP, the IIEF-5 score increase tended
to be more pronounced in subjects with higher PP quartiles
(class 1 versus 3, 𝑃 = 0.031; Figure 7). The efficacy of
vardenafil in subjects with low and mid-high CV risk is
compared in Figure 8. Vardenafil proved the noninferiority
in the primary endpoint of the study; an essentially identical
change (increase) in IIEF-5 score was observed for both low
and high CVR subjects. As expected, the baseline difference
in IIEF-5 score led to a significantly lower percentage of
subjects achieving a normal IIEF-5 score in last visit among
the high risk men. Nevertheless, there was no difference in
the percentage of subjects achieving an improved ED class.
Response to vardenafil was equal in men both with and
without vascular disease on penile duplex ultrasound (data
not shown).
3.7. Is Vardenafil Safe in High CV Risk Subjects? The most
common treatment-emergent adverse events, occurring in
≥2% of any treatment group (safety population), were
headache (4.1%) and flushing (3.6%). In the six-month
treatment period, 54 patients were lost to follow-up or
discontinued the medication due to its cost. Overall, 14
discontinued vardenafil (<6% of overall population) because
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Figure 7: Change in IIEF-5 score in the population stratified according to quartiles of pulse pressure.
PP population
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Lost at follow-up Lost at follow-up
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n = 108
n = 118 n = 79
n = 75
Δ-IIEF = 6.11 ± 0.53 Δ-IIEF = 5.70 ± 0.72
IIEF normalization = 45% IIEF normalization = 23%
Side effects = 5.9% Side effects = 6.2%
Severe adverse events = 0% Severe adverse events = 0%
Change in ED severity class = 82% Change in in ED severity class = 78%
P = 0.678
P = 0.011
∗
P = 0.555
P = 0.798
n = 153 n = 98
n = 35 n = 19
(CVR < 10% (CVR > 10% ≥ III)
Allocated to vardenafil n = 253
vardenafil n = 10 vardenafil n = 4
MACE—class MACE—class< III)
Figure 8: Comparisons of efficacy and safety for vardenafil treatment in subject with low versus high cardiovascular risks.
of reported drug-related non-serious adverse events such as
headache and facial and neck flushing after the first three
doses. No serious adverse event was reported during the
study.
A small reduction in diastolic blood pressure (82.76 ±
8.31 versus 80.96 ± 6.79; 𝑃 = 0.043) was observed during
treatment. There was also a slight reduction in systolic blood
pressure (131.9±15.0 versus 129.1±10.6mmHg; 𝑃 = 0.058),
which however was not statistically significant. There was no
significant change in PP (49.30±10.81 versus 48.35±8.83;𝑃 =
NS) following six months of on-demand vardenafil adminis-
tration. No significant difference was seen in discontinuation
rate, side effects, and follow-up loss frequencies between low
and mid-high CV risk classes (Pearson’s 𝜒2 test), indicating
that the drug is safe and well tolerated in ED subjects with an
elevated cardiovascular risk (Figure 8).
4. Discussion
This Italian nationwide observational study on a large cohort
of middle-aged men suffering from ED demonstrates that
ED severity is closely correlated with increased CV risk. This
correlation is the result of the combined effect of diabetes,
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hypertension, arterial stiffness, and hypogonadism, mea-
sured using a validated regional risk score chart developed by
the Progetto Cuore. The SIAMS-ED survey also revealed, for
the first time, that androgens are significant contributors to
arterial stiffness of EDpatients that exhibit an alteration of the
HPG axis. In contrast, we showed that, when CV risk is cor-
rectly estimated, the diagnosis of metabolic syndrome does
not add any useful information.Themajor contribution of the
diagnostic criteria for metabolic syndrome was found to be
increased waist circumference, a causative factor of hypoan-
drogenism.
This study is among the very few prospective, multicentre
studies to offer a real-life estimate of global CV risk and
prevalence of metabolic syndrome in ED population. Com-
pared to other Italian surveys [22, 32], we found a higher
prevalence of subjects at a moderate risk of MACE, but a
substantially similar prevalence in the diagnosis of metabolic
syndrome compared to non-ED subjects.
Finally, with the limitation of a nonrandomized, single-
arm trial, this real-life setting interventional study showed
that vardenafil’s response appears durable, preserved inde-
pendent of the severity of cardiometabolic impairment, and
safe even in high CV risk subjects. The latter issues are of
particular relevance for practicing physicians in view of the
growing interest for long-term, choric use of PDE5i in aging
men with cardiovascular disease.
4.1. CVR in the ED Population. ED has been identified as an
independent risk factor for CVD [9]. In the prostate cancer
prevention trial, men with ED were reported to have an
approximate two times higher risk of CVD thanmen without
ED [33]. Similarly, in patients seeking treatment for ED, the
presence of arteriogenic ED was significantly associated with
an increased risk of MACE [34]. Based on these associations,
international guidelines recommend in-depth risk factor
screening in all subjects with ED prior to symptomatic treat-
ment with PDE5i [35]. However, knowledge of the detection
rate of previously unknown underlying medical conditions
in men with ED is limited to retrospective, single-centre
studies. In the Men’s Attitudes to Life Events and Sexuality
(MALES) study, 64% of men with ED self-reported one or
more underlying condition [36]. In the SIAMS-ED survey,
nearly half of the ED population had a previous diagnosis
of a vasculogenic or metabolic disorder and 42% were under
medical treatment, with figures similar to those of the general
population. However, we also diagnosed unknown cardio-
vascular or metabolic disorders in 24% of our ED subjects
(Figures 2 and 3). These numbers are nearly double those
reported in a recent UK study [37], where the rate of
discovery of previously unknown conditions was 11.53%.
The discrepancy is likely due to methodological differences,
rather than regional characteristics. The SIAMS-ED study
was in fact prospectively designed, while Kirby’s study was
based on disease registry. Finally, some studies tended to
show a decline in the rate of discovery or association of CVD
with ED, after PDE5 became widely available [38]. Our data
do not support this finding, underlying the largely unmet
need of CV risk prevention in ED patients.
4.2. PP and Androgens. A relationship between testosterone
and arterial stiffness was first suggested by Rosano et al.
[39], who found that short-term intravenous testosterone
administration reduced time to exercise-induced myocardial
ischemia, probably due to a direct coronary artery-relaxing
effect. Androgen withdrawal has also been associated with
reduced large artery compliance [40]. Longitudinal analysis
revealed that the effects of testosterone on arterial stiffness
could still be detected, in healthy subjects, when testosterone
was measured 5 to 10 years later, supporting a long-term
influence [41].
We were the first to document that the association
between testosterone and PP had implications for arterio-
genic ED [18, 42], as also confirmed by an increased aug-
mentation index measured by peripheral arterial tonometry
[43]. In the present study, we showed, for the first time, that
the association between PP and T was maintained even when
adjusted for waist circumference (Table 4). In addition, we
demonstrated that the hypoandrogenism developing in the
high CV risk subjects is not accompanied by LH rise, sug-
gesting hypothalamic-pituitary insufficiency (Figure 5) [20,
30, 44]. These associations were maintained even after cor-
rection for the use of antihypertensive medications. PP thus
seems to be a reliable marker of cardiovascular and sexual
health, with higher values associated with altered testos-
terone.
Our study is also the first to address, whether the
association between PP and hypogonadism in ED depends
on systolic or diastolic components of BP. The relationship
between testosterone levels and hypertension is not com-
pletely clear in the available literature. Some studies have
found no association [18, 45, 46], neither a negative [47] nor
a positive association [48, 49] between systolic blood pressure
and androgens. In contrast, the majority of studies found
a weaker association with diastolic blood pressure. Our
study confirms that the main contributor to elevated PP is
systolic hypertension, although diastolic hypertension was
more frequent in hypogonadal men. We also showed that the
association between PP and androgens was maintained when
PP was normalized for diastolic blood pressure values and it
was independent of medications known to affect androgen
status [50].
4.3. Cardiovascular versus Metabolic Diagnostic Categories.
There is an open debate on the value of metabolic syndrome
diagnosis in various clinical settings [51–53]. In contrast with
some previous studies [6], the SIAMS-ED survey seems to
show that the CV risk chart score is better than the metabolic
syndrome criteria in predicting the severity of ED [7, 54].
This finding is consistent with the recent publication of The
emerging risk factors collaboration, who found that, when
additional information is available from standard risk score,
simple adipositymeasures (BMI or waist circumference) pro-
vide little or no additional information on CV risk in the gen-
eral population [55].This prospective study of 221934 subjects
concluded that CV risk scores which omit adipositymeasures
(e.g., Framingham, SCORE, PROCAM, Reynolds and ISS-
Progetto Cuore Engine) are not further improved by includ-
ing single or combined measures of adiposity. Our survey
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extends this finding to ED subjects, showing that a good CV
risk chart is a better prognostic tool thanmetabolic syndrome
criteria. The major contribution of metabolic impairment,
through an increased waist circumference, was that of further
reduction of androgen levels [20]. The circle is then closed,
considering low testosterone levels to be a novel determinant
of increased PP for middle-agedmen suffering from ED [20].
Given the recently described association between reduced
androgens and cardiovascular abnormalities and mortality
[56, 57], all hypertensive patients should be screened for
hypogonadism [20].
4.4. Response to Vardenafil. The increasing number of risk
factors for CVD has been associated with a lower response to
conventional treatments [24, 58].Despite this poor prognosis,
we tested vardenafil on demand in middle-aged and older
patients who were enrolled independent of their prior use
of any phosphodiesterase type 5 inhibitors (PDE5-i) and
stratified according to the severity of CVR and found that
clinical response was equally detectable regardless of the
presence or absence of penile vascular disease (Figure 6).
The efficacy and safety of vardenafil have been tested in
several randomized trials, includingmenwith various under-
lying conditions [25, 59–63]. All these studies documented
efficacy that was retained irrespective of the medication used
to treat the underlying disorders. However, all these studies
were relatively short (12 weeks) and none used a recognized
CV risk chart score to stratify at-risk patients. In addition,
this is the first time PP quartiles have been assessed as an
additional surrogate marker of CVR.
Our study, being non-randomized and single-arm, could
not formally assess efficacy; however our data consistently
with previous observation [64] confirmed that vardenafil
improved erections and was well tolerated in a real-life
population of men with cardiovascular impairment, many of
whom were also taking concomitant medications. In addi-
tion, we showed, in high CV risk classes, normally excluded
in sponsored trials, that vardenafil is safe and well tolerated
regardless of the use of concomitant antidiabetic medica-
tion [65], multiple antihypertensives [60], or lipid-lowering
agents [66]. Specifically, we found no difference in response
in statin users than in nonusers (Figure 8).
Vardenafil was well tolerated over the 6-month period,
with a low incidence of adverse events. This underestimated
incidence might be due to the fact that data were only
recorded at follow-up visits; other studies have shown that
a greater number of serious versus mild adverse events are
reported by physicians during postmarketing drug surveil-
lance [67]. In our cohort, the treatment-emergent adverse
events weremostlymild-to-moderate headache and flushing,
affecting <5% of the treated population. There were no drug-
related serious adverse events. Furthermore, SBP, diastolic
blood pressure, and heart rate, particularly relevant in the
high CV risk group, were not significantly altered by varde-
nafil treatment (Figure 8).The latter findings are of particular
interest given the preliminary data showing that PDE5i could,
in the future, be tested as antiremodelling agents [68].
4.5. Limitations. This study has several limitations. Regard-
ing the observational study, we acknowledge that PP is not
as accurate as other surrogate measures of arterial stiffness,
including ultrasonography and tonometry. However, it is an
easy, fast, and inexpensivemeasurement which can be readily
obtained in wider populations for epidemiological purposes.
A second limitation is that most studies have explored the
association between androgen and large arteries, whereas
PP or CDU resistance index measures compliance of small
peripheral arteries. A third weakness is that only testosterone
was recorded and given that SHBG could be significantly
altered in diabetic patients; this aspect may have lowered the
power of any associations with androgens.
The major limitations of the interventional study are that
it was neither randomized nor had a placebocontrolled group
(singlearm, open label). However, efficacy over placebo,
which is well established, was not our primary. The primary
objective was in fact to compare responsiveness in different
CV risk classes. As the study included nonnaı¨ve patients with
ED, the efficacy and safety may have been somewhat biased
by any prior use of another PDE5i. However, prior-PDE5i
users were equally distributed among the two groups (low
and high CV risk groups). In any case, we believe that this
inclusion criteria would have reduced, rather than increased,
the response rate and therefore should have not altered the
direction of the observed trends. Finally, only one post-
treatment evaluation was available for efficacy assessment,
compared to the monthly visits performed in many trials.
However, this is much closer to follow-up times in a real-life
public outpatients clinics. Furthermore, our study is among
the few exploring the effects after six months of treatment, as
the vast majority terminate their observations after 3months.
Once again, this design, if carrying any relevant effect, would
have been in the direction of lowering the response rate. The
efficacy of vardenafil in difficult-to-treat populations would
thus seem to be indirectly confirmed.
5. Conclusions
The SIAMS-DE study demonstrates for the first time in
large multicentre independent prospective analysis that PP
is related to many aspects of cardiometabolic compensation,
such as BMI, waist circumference, and testosterone levels,
which are in turn related to a higher incidence of MACE in
the general and ED population. We found that a progressive
defect in hypotalamo-pituitary-gonadal feedback is associ-
ated with increased CV risk and contributes to increased
cardiovascular stiffness through an association with systolic,
but not diastolic, BP.This study gives another insight into the
fact that the presence and severity of ED should be considered
a sentinel symptom of cardiometabolic involvement and
should merit hormonal assessment and tough intervention
[20, 23].This study demonstrates that concomitant antihyper-
tensive treatment does not affect the efficacy of vardenafil and
that the improvement in IIEF-5 is preserved even in higher
CV risk men. This aspect is very new, as PDE5-i are usually
found to lose efficacy in the presence of severe concomitant
conditions like hypertension, diabetes, dyslipidaemia, or
CAD. In conclusion, we demonstrated that vardenafil is a
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valuable option for the treatment of ED even in high-risk,
difficult-to-treat populations.
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